BTIG analyst Yun Zhong maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report) yesterday and set a price target of $35.00. The company's shares closed last Tuesday at $13.22. According to TipRanks.com, Zhong is ranked 0 out of 5 stars with an average return of -20.6% and a 19.7% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Mereo Biopharma Group Plc, and Taysha Gene Therapies. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Anavex Life Sciences with a $39.80 average price target, a 182.7% upside from current levels.
https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-anavex-life-sciences-avxl?utm_source=advfn.com&utm_medium=referral
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Anavex Life Sciences Charts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Anavex Life Sciences Charts.